# Neurocrine Biosciences (NBIX): value investors who own it

1 value investor held Neurocrine Biosciences in their Q3 2026 13F, led by Dodge & Cox. See who bought, sold and how ownership has changed by quarter.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Dodge & Cox | 0.5% | $941m | Added +2.3% | 12 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-09-14 | ABERNETHY MATT | Chief Financial Officer | Sold | 2311 | $363k |
| 2026-09-14 | Boyer David W. | Chief Corp. Affairs Officer | Sold | 826 | $130k |
| 2026-09-09 | BENEVICH ERIC | Chief Commercial Officer | Sold | 2154 | $333k |
| 2026-07-28 | Norwalk Leslie V | Director | Sold | 1250 | $228k |

## Fund holders

| Fund | Manager | Weight | Value | As at |
| --- | --- | --- | --- | --- |
| Dodge & Cox Global Stock Fund | Dodge & Cox | 0.2% | $25.5m | 2026-06-30 |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/nbix). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.